soul trial semaglutide Forecasting Milestones: A Predictive Analysis for Early Termination of the Study | Diabetes Therapy SOUL: Oral Semaglutide Cuts CV

Retatrutide (Eli Lilly), a triagonist currently in phase III clinical trials (TRIUMPH-1 NCT05929066 and others 3 ) adds a glucagon receptor agonist to its mechanism of action, promising an even greater impact on weight loss

The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans

In the landmark Select study, Wegovy reduced the risk of major cardiovascular events (MACE) by 20%

Some providers recommend administering BPC-157 in traditional subcutaneous injection sites such as the abdomen or thigh

Retatrutide asks whether triple receptor agonism can create a new efficacy ceiling

Development Status, Safety, and Future Outlook Mazdutide is currently in clinical development and has not yet received regulatory approval for general use